Competitive problems in the drug industry: hearings before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, United States Senate, Ninety-first Congress, first session ... |
From inside the book
Results 1-5 of 50
Page 11642
... acquisition cost is very hard to pin down . Quoted wholesale prices often do not reflect the real acquisition costs . The individual pharma- cist , or the buyer for a large chain or a large hospital , may be able to get the drug at well ...
... acquisition cost is very hard to pin down . Quoted wholesale prices often do not reflect the real acquisition costs . The individual pharma- cist , or the buyer for a large chain or a large hospital , may be able to get the drug at well ...
Page 11643
... acquisition cost of drugs . Would this difficulty not be eliminated , and would more money be saved , if the government itself bought the drugs and distirbuted them through the regular commercial channels ? For example , the druggist ...
... acquisition cost of drugs . Would this difficulty not be eliminated , and would more money be saved , if the government itself bought the drugs and distirbuted them through the regular commercial channels ? For example , the druggist ...
Page 11649
... cost of the product dispensed and the MAC limit on that drug . We estimate that Federal and State savings during the first full year of this program would be about $ 49 million . With respect to acquisition costs and the dispensing fees ...
... cost of the product dispensed and the MAC limit on that drug . We estimate that Federal and State savings during the first full year of this program would be about $ 49 million . With respect to acquisition costs and the dispensing fees ...
Page 11650
... acquisition cost and their concern about downward revisions in their drug product reimbursement base with- out compensating increases in dispensing fees , and we certainly recog- nize the need for equity in dispensing fees regardless of ...
... acquisition cost and their concern about downward revisions in their drug product reimbursement base with- out compensating increases in dispensing fees , and we certainly recog- nize the need for equity in dispensing fees regardless of ...
Page 11670
... acquisition cost requirement is effectuated . Mr. Chairman , I want to make it clear to you and this committee , as we have attempted to make it clear to HEW in our comments on the MAC proposed regulations , that we believe actual ...
... acquisition cost requirement is effectuated . Mr. Chairman , I want to make it clear to you and this committee , as we have attempted to make it clear to HEW in our comments on the MAC proposed regulations , that we believe actual ...
Other editions - View all
Common terms and phrases
actual acquisition cost agencies antisubstitution laws APhA average wholesale price bioavailability bioequivalence brand name central CHAIRMAN competitive Defense develop Digoxin dispensing Drug Administration drug product Drug Research Board effective erythromycin established Food and Drug formulary Gaylord Nelson GORDON Government Government-wide hospital implementation inspection Interagency Labs local purchases MAC price MAC program MAC regulations Manufacturing Practices Maximum Allowable Cost Medicaid MEDICAL AND NONPERISHABLE medical items Medicare meeting ment MICHELOTTI patient percent Pharmaceutical pharmacists pharmacy physician PITTMAN prednisone prescribed present problems procurement professional proposed regulations purchasing quality assurance quality assurance program recommendations reimbursement resolution responsibility savings SCHMIDT Secretary WEINBERGER selection Small Business Sorett specific standards statement STETLER subcommittee substitution laws Supply Management Committee Tablets task group therapeutic equivalence tion TRYGSTAD WHITWORTH
Popular passages
Page 12087 - Since many agencies, including the Food and Drug Administration in the Department of Health, Education and Welfare, in which the appellant was employed, have nothing to do with national security, the Act of 1950 has nothing to do with them. The authorization to bring "other...
Page 12159 - Register, to be In the public interest in connection with the performance of duties imposed on that agency by law.
Page 11700 - I AM PLEASED TO BE HERE TODAY AND TO HAVE THE OPPORTUNITY TO ASK QUESTIONS OF SECRETARY JACKSON.
Page 12328 - Engineering before the Subcommittee on Health of the Senate Committee on Labor and Public Welfare, 94th Cong., 1st Sess.
Page 12055 - The hearing need not be conducted according to technical rules relating to evidence and witnesses. Any relevant evidence shall be admitted if it is the sort of evidence on which responsible persons are accustomed to rely in the conduct of serious affairs, regardless of the existence of any common law or statutory rule which might make improper the admission of such evidence over objection in civil actions.
Page 11663 - OF THE SELECT COMMITTEE ON SMALL BUSINESS, Washington, DC The subcommittee met, pursuant to notice, at 10 am, in room 2221.
Page 11925 - Action is pleased to have the opportunity to present its views on the $12.7 billion supplemental appropriation for America's efforts in Vietnam.
Page 11732 - STATEMENT OF ALEXANDER M. SCHMIDT, MD, COMMISSIONER, FOOD AND DRUG ADMINISTRATION; ACCOMPANIED BY J. RICHARD GROUT, MD, DIRECTOR, BUREAU OF DRUGS; PETER BARTON »HUTT, ASSISTANT GENERAL COUNSEL; LLOYD B. TEPPER, MD, ASSOCIATE COMMISSIONER FOR SCIENCE; BARRETT SCOVILLE, MD, ACTING DIRECTOR OF THE DIVISION OF BUREAU OF NEUROt PHARMACOLOGICAL PROJECTS; AND ROBERT WETHERELL, DIRECTOR, OFFICE OF LEGISLATIVE SERVICES Dr.
Page 12055 - substantial evidence" means : Evidence consisting of adequate and well controlled investigations, including clinical investigations by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling...
Page 12054 - The means employed shall be such as to allow, to the extent practicable, eligible persons to secure health care in the same manner employed by the public generally, and without discrimination or segregation based purely on their economic disability.